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GENETIC DISORDERS – DEVELOPMENT
Hereditary amyloidosis in early childhood associated with a
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Hereditary amyloidosis in early childhood associated with a
novel insertion-deletion (indel) in the fibrinogen Aa chain gene.
Background. Systemic amyloidosis occurring in early child-
hood is extremely rare, and is usually of AA type complicating
chronic inflammatory diseases. We report the molecular basis
of amyloidosis in a Korean girl who presented at 7 years of
age with asymptomatic proteinuria and developed amyloid hep-
atomegaly and end-stage renal failure within 2 years.
Methods. Renal biopsy showed enlarged glomeruli virtually
replaced by amyloid, but without interstitial or vascular involve-
ment. The histologic appearance was identical to that seen in
patients with hereditary fibrinogen Aa chain Glu526Val amy-
loidosis, and the amyloid deposits stained specifically with an-
tibodies to fibrinogen. Mutations were sought in the genes of
the amyloidogenic proteins, transthyretin, apolipoprotein AI,
lysozyme and fibrinogen Aa chain genes by polymerase chain
reaction (PCR) and sequencing.
Results. A unique frameshift insertion-deletion (indel) muta-
tion was identified in one allele of her fibrinogen Aa chain gene,
which encodes a partly novel peptide and a premature stop sig-
nal, similar to the two previously reported amyloidogenic point
deletions at codons 522 and 524 in this molecule. The mutation
was absent in samples verified to be from her parents, indicating
that it had occurred de novo.
Conclusion. This is the first description of hereditary fib-
rinogen Aa chain amyloidosis in an Asian individual, and the
distinctive renal histology offered a strong clue to the diagno-
sis. The disease is potentially curable by combined hepatorenal
transplantation.
Systemic amyloidosis is a heterogeneous group of dis-
eases that frequently present with renal dysfunction. The
most common forms are acquired, and comprise AL and
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AA types associated with monoclonal gammopathies and
chronic inflammation, respectively, but there are numer-
ous hereditary types in which the amyloid fibrils are de-
rived from genetic variants of various proteins, including
transthyretin, apolipoprotein AI and AII, fibrinogen Aa
chain, lysozyme, gelsolin, and cystatin C [1–4]. Presently,
treatment of amyloidosis is directed toward reducing pro-
duction of the respective amyloid fibril precursor protein,
for example chemotherapy targeting clonal plasma cells
in AL-amyloidosis, and liver transplantation to correct
the inborn error in some forms of hereditary amyloido-
sis, emphasizing need for accurate diagnosis [5–9]. The
prevalence of AL-amyloidosis increases with age, and it
is exceptionally rare below the age of 30 years. Hered-
itary amyloidosis is transmitted dominantly and usually
presents in middle age with neuropathy in patients with
transthyretin mutations, or nephropathy in patients with
mutations in the genes for apolipoprotein AI or AII,
lysozyme, and fibrinogen Aa chain [10]. In children most
reports of renal amyloidosis have been of AA type, asso-
ciated with inflammatory disorders such as juvenile idio-
pathic arthritis [11, 12].
Some mutations in the fibrinogen Aa chain gene
(FGA) (Unigene Representative Sequence Accession
Number NM 000508.2) have been reported to cause
hereditary renal amyloidosis in eight multiplex kindreds
[2, 7, 13–18], but it has lately become clear that most pa-
tients with hereditary fibrinogen Aa chain amyloidosis
have no apparent family history, and are frequently mis-
diagnosed as having AL-amyloidosis [2]. All previously
reported patients with fibrinogen Aa chain amyloidosis
have been of non-Asian, mainly European or Western
Hemisphere origin, and have included one Peruvian-
Mexican and one African American family [13, 19] with
onset of symptoms in adulthood except one 12-year-old
child with a single nucleotide deletion [15].
We report here a novel de novo complex rearrange-
ment insertion-deletion (indel) in FGA detected in a
7-year-old girl in Korea with systemic amyloidosis, who
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Fig. 1. Renal biopsy. Hematoxylin and eosin (A) stain and electron micrograph (B) show greatly enlarged glomeruli substantially replaced by
amyloid, further confirmed in Congo Red stain (C) and the same section viewed under crossed polarized light (D) showing typical apple green
birefringence.
presented with nephropathy. This characterization of her
disease indicates that she may be curable through com-
bined liver and kidney transplantation.
METHODS
Clinical presentation
A 7-year-old girl was found to have proteinuria on uri-
nalysis during a routine school medical examination. She
had had intermittent eyelid edema and foamy urine for
1 year, but there was no evidence of chronic inflammatory
disease, or of a family history of renal disease. She was
initially normotensive and had no organomegaly or lym-
phadenopathy. Laboratory findings confirmed nephrotic
syndrome with serum albumin 2.5 g/dL, hypercholes-
terolemia (serum cholesterol 350 mg/dL), and protein-
uria (random urine protein/creatinine ratio 3.8), along
with anemia (hemoglobin 9.7 g/dL) and moderately de-
creased creatinine clearance (69.8 mL/min/1.73 m2).
Her liver function tests were normal. Ultrasonography
demonstrated enlarged kidneys and a coarse echogenic
pattern in the liver that suggested an infiltrative process.
Hemotoxylin and eosin staining of a renal biopsy showed
massive glomerular enlargement without vascular or in-
terstitial involvement, which was shown to be due to
amyloid deposits with Congo Red; electron microscopy
further showed massive accumulation of nonbranching
fibrils consistent with amyloid in the mesangium and
subendothelium (Fig. 1). The amyloid deposits did not
stain with antibodies to amyloid A protein or to j and k
immunoglobulin light chains.




Fig. 2. Sequence (reverse complement) trace
of part of exon 5 of fibrinogen Aa chain gene.
(A) Direct sequence of polymerase chain re-
action (PCR) product from the patient. (B)
The mutant allele cloned into plasmid with
insertion boxed and the final unmutated nu-
cleotide (arrow). (C) The cloned normal allele
from the patient showing the portion deleted
from the mutant allele (bold box).
Immunoelectrophoresis and immunofixation of serum
and urine were normal, as were Mantoux test, plasma
C-reactive protein, serum amyloid A protein concen-
trations, autoimmune serology, plasma fibrinogen con-
centration, and a coagulation screen. Echocardiography
and an electrocardiogram showed no evidence of cardiac
amyloid. Bone marrow biopsy revealed no evidence of
a B-cell dyscrasia or of amyloid deposits. She received
supportive care, including an angiotensin-converting en-
zyme (ACE) inhibitor, but her condition deteriorated
over the following 2 years during which she became hy-
pertensive and required peritoneal dialysis for end-stage
renal failure. The undetermined etiology of her amy-
loid was reevaluated at this stage and included DNA
screening of genes associated with hereditary forms of
amyloidosis. Further immunohistochemical studies were
performed using a panel of antibodies to proteins impli-
cated in hereditary amyloidosis.
DNA screening
DNA was isolated with a QIAamp DNA Mini-Kit
(Qiagen, Valencia, CA, USA) from ethylenediaminete-
traacetic acid (EDTA)–treated whole blood of the pa-
tient, her sister, and her parents. The coding regions of
the genes for transthyretin (exons 2, 3, and 4) apolipopro-
tein A1 (exons 3 and 4), lysozyme (exon 2), and part of
exon 5 of fibrinogen Aa chain were amplified by poly-
merase chain reaction (PCR) and sequenced as previ-
ously described [2], using a reverse sequencing primer
in the case of fibrinogen Aa chain (5′-ctcatctgccattt
tatagct) (c.1828 1848). Products containing a rearrange-
ment were cloned into pGEM T-Easy Vector System II
Kit (Promega, Madison, WI, USA) according to the man-
ufacturer’s instructions. Colonies containing an insert
were grown overnight in selective media and DNA was
prepared using a QIAprep Spin Miniprep Kit (Qiagen)
according to the manufacturer’s instructions. Plasmids
were sequenced using a reverse primer. Sequences were
analyzed by comparison with GenBank, OMIM and
HGMD databases, and the specialist fibrinogen database
GEHT [20].
RESULTS
The apolipoprotein AI, transthyretin, and lysozyme
gene sequences were normal wild-type. However, her
fibrinogen Aa chain gene contained a heterozygous in-
del that resulted in the appearance of two superimposed
sequences after amino acid 516 (Fig. 2 shows the re-
verse complement sequences obtained). Cloning and se-
quencing the two alleles separately revealed that one
was normal wild-type and that other contained a novel
replacement mutation (c.1636 1650del,1649 1650insCA)
comprising a 17 bp deletion plus 2 bp (CA) insertion
(shown as reverse complement TG insert in Fig. 2).
This is predicated to result in a frameshift and a prema-
ture stop codon (p.517 522delinsQSfsX548). The parents
and sister were homozygous for the normal wild-type
allele, and relationship testing (Wiltech-Bio, Montrose,
Scotland) (data not shown) confirmed that the patient
carries a de novo mutation.
The amyloid deposits in the renal biopsy stained specif-
ically with antibodies to fibrinogen (Fig. 3), but not with
antibodies to other known hereditary amyloid proteins
(not shown). Combined hepatorenal transplantation, to
replace her renal function and to eliminate the hepatic
source of her amyloidogenic variant protein, is presently
under consideration.
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Fig. 3. Congo Red–positive glomerular amyloid deposits (A) and ad-
jacent tissue section stained both with Congo Red and with antibodies
to fibrinogen protein (B).
DISCUSSION
This case expands the phenotypic and genotypic spec-
trum of hereditary fibrinogen Aa chain amyloidosis, and
is notable for being due to a de novo mutation, and for
being the first description of this type of amyloidosis in an
Asian individual. It also illustrates the multidisciplinary
clinical and laboratory practice that is required to obtain
definitive characterization of fibril type in patients with
amyloidosis and emphasizes how accurate diagnosis of
amyloid type can have major implications for treatment.
A diagnosis of amyloidosis was not suspected on clin-
ical grounds in this very young patient who had no
prior disease or family history. To identify the amy-
loid fibril type, further investigations were required. Im-
munohistochemical typing is the most accessible method
for determining amyloid fibril type but it is subject to
many pitfalls. Whereas it was possible to exclude AA-
amyloidosis in our patient immunohistochemically since
AA-amyloid is reliably characterized by this method, the
lack of an identifiable monoclonal gammopathy or of pos-
itive immunostaining for j or k light chains did not rule
out her having AL type. While histologic studies have
suggested a modest degree of correlation between certain
distributions of amyloid within the kidney and particular
fibril types in general, the distinctive pattern of Congo
Red staining in this patient’s renal biopsy, with a striking
absence of vascular and interstitial deposits, gave a pow-
erful clue to the diagnosis. This distinctive pattern was
identical to that observed in over 40 patients we have eval-
uated with hereditary fibrinogen Aa chain amyloidosis
associated with the Glu526Val variant [2]. The intensity
of immunohistochemical staining in fibrinogen Aa chain
amyloidosis is variable in our experience, but unequivo-
cal specific staining of the amyloid deposits was obtained
in this particular case. Apart from her remarkably young
age and rapid disease progression, this patient’s pheno-
type and laboratory findings were typical for fibrinogen
Aa chain amyloidosis.
DNA analysis was a vital component of the diagnostic
process, and many cases of hereditary amyloidosis will be
missed unless genetic studies are performed routinely. We
previously reported that 10% of patients among a series
of 350 individuals who had been thought to have AL-
amyloidosis were actually shown to have various forms
of hereditary amyloidosis after additional DNA analy-
sis had been performed; one half of these patients had
fibrinogen Aa chain Glu526Val [2]. Although this latter
form of hereditary amyloid was originally described as
a high penetrance dominantly inherited syndrome, it is
now evident that the typical patient has no family history,
probably due to reduced penetrance. Disease associated
with the Glu526Val variant, the most common form of fib-
rinogen Aa chain amyloidosis, typically presents in mid-
dle age with renal dysfunction; hepatic amyloid develops
in only a very small proportion of cases, and the heart is
not involved. The age of onset and progression to end-
stage renal failure in the present patient occurred at a
younger age than has previously been reported in any
type of hereditary amyloidosis, although one child with
hereditary fibrinogen Aa chain amyloidosis due to the de-
letion mutation c4897delT presented at age 12 years [15].
This is the first complex mutation in the fibrinogen
Aa chain gene associated with amyloidosis. Many non-
amyloidogenic mutations in this gene have been iden-
tified (see http://www.geht.org/databaseang/ﬁbrinogen),
and those that are associated with amyloidosis are located
in a relatively small part of the molecule. Other amyloido-
genic variants are Arg554Leu [13] and Glu540Val (unre-
ported observations) caused by missense point mutations,
and those associated with two point deletions resulting in
frame shifts at codon p524 (c4904delG) [18] and codon
p522 (c4897delT) resulting in a novel peptide in the amy-
loid deposits [15]. The present complex indel encodes a
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Fig. 4. An alignment of known mutations in part of exon 5 of the fibrinogen Aa chain gene. Locations of amyloidogenic (bold italic) mutations and
other nonamyloidogenic pathogenic mutations in genetic proximity to the new insertion and deletion (indel). Italics are nonamyloidogenic; WT
is partial wild-type normal sequence; numbers to left are amino acid locations of deletions; Numbers above WT sequence show point mutations
reported in the region. |Homology; ∗Termination codon; (−) spaces inserted to allow alignment.
peptide that is nearly identical with that predicted by the
p524 (c4897delT) and p522 (c4904delG) frameshift dele-
tions (Fig. 4). Sufficient amyloid laden tissue for further
analyses was not available from our patient.
The bulk of experience in clinical management of
hereditary fibrinogen Aa chain amyloidosis has been
obtained in patients with the Glu526Val variant, whose
clinical disease is in the main restricted to renal failure.
However, although end-stage renal failure typically does
not occur until the sixth or seventh decade, renal trans-
plants often fail due to amyloid in less than 10 years. By
contrast, orthotopic liver transplantation, performed si-
multaneously with kidney transplantation for end-stage
renal failure [7, 21], offers the prospect of cure since fib-
rinogen and its amyloidogenic variants are produced in
the liver.
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